- Mannen onder endocriene therapie (aangevraagd door onco of uro)
- Vrouwen (indien zeer lage waarden of > 50 ng/dL ter controle)
- Kinderen
Leeftijd | Mannen | Vrouwen |
---|---|---|
> 79 j | 157.0-913.0 ng/dL | 6.0-25.0 ng/dL |
69 j - 79 j | 218.0-926.0 ng/dL | 6.0-25.0 ng/dL |
59 j - 69 j | 218.0-929.0 ng/dL | 6.0-25.0 ng/dL |
51 j - 59 j | 219.0-929.0 ng/dL | 6.0-25.0 ng/dL |
49 j - 50 j | 219.0-929.0 ng/dL | 5.8-47.6 ng/dL |
50 j - 51 j | 219.0-929.0 ng/dL | 9.0-55.0 ng/dL |
40 j - 49 j | 235.0-929.0 ng/dL | 5.8-47.6 ng/dL |
39 j - 40 j | 235.0-929.0 ng/dL | 11.0-56.0 ng/dL |
30 j - 39 j | 267.0-929.0 ng/dL | 11.0-56.0 ng/dL |
17 j - 30 j | 267.0-929.0 ng/dL | 11.0-59.0 ng/dL |
15 j - 17 j | 185.0-886.0 ng/dL | 8.0-63.0 ng/dL |
13 j - 15 j | 33.0-585.0 ng/dL | 9.0-49.0 ng/dL |
11 j - 13 j | 7.0-747.0 ng/dL | 6.0-64.0 ng/dL |
9 j - 11 j | 2.0-57.0 ng/dL | 2.0-42.0 ng/dL |
7 j - 9 j | 3.0-23.0 ng/dL | 3.0-29.0 ng/dL |
4 j - 7 j | 3.0-26.0 ng/dL | <20.0 ng/dL |
12 md - 4 j | 3.0-20.0 ng/dL | <18.0 ng/dL |
6 md - 12 md | 3.0-12.0 ng/dL | 3.0-20.0 ng/dL |
3 md - 6 md | 3.0-89.0 ng/dL | <12.0 ng/dL |
7 d - 3 md | 14.0-363.0 ng/dL | <20.0 ng/dL |
< 7 d | 6.0-78.0 ng/dL | 6.0-78.0 ng/dL |